ContraFect

ContraFect Inventory/Revenue

Inventory to Revenue Ratio of ContraFect (CFRXQ) as of Oct 19, 2026.

Inventory/Revenue

-

Last updated:

Inventory to Revenue Ratio of ContraFect is 2026 - . Inventory to Revenue Ratio of ContraFect was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ContraFect Stock analysis

What does ContraFect do? ContraFect Corp, based in Yonkers, New York, is a clinical-stage biotechnology company focused on developing direct lytic agents (DLAs) such as lysins and amurin peptides to treat life-threatening antibiotic-resistant infections. The company, listed in 2014, employs 23 people and is advancing its lead candidate exebacase (CF-301) for MRSA bloodstream infections and chronic prosthetic joint infections, alongside CF-370 targeting gram-negative bacteria. ContraFect is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ContraFect stock

On Eulerpool you can find the complete historical development of Inventory to Revenue Ratio ContraFect since 2006 – with annual values, charts, and detailed analysis.

The Inventory/Revenue ratio shows what percentage of revenue is held as inventory. Rising ratios may indicate slowing demand or inventory management issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Inventory to Revenue Ratio's ContraFect with sector peers and the industry average to assess whether it is attractive.

To evaluate Inventory to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Inventory to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — ContraFect

All Key Metrics — ContraFect